skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Washington, D.C., USA- January 13, 2020: FDA Sign outside their headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.

Diagnostics companies working on tests for the novel coronavirus that could be distributed over the counter got fresh guidance on 29 July, as the US Food and Drug Administration released a new template that shows what emergency use authorization (EUA) submissions for these tests might look like.

The template addresses the design and development of COVID-19 diagnostic tests that can be performed entirely at home or in other non-lab settings, such as offices or schools, as well as those that won’t require a physician’s prescription. It makes recommendations about validation procedures, clinical trial designs and test performance evaluation strategies, among other topics.

The FDA has already authorized some COVID-19 diagnostics that allow for home sample collection, with the first arriving in April. However, those tests still must be physician-prescribed and shipped to a lab for analysis.  (Also see "First US Home Collection COVID-19 Test Gets Green Light" - Medtech Insight, 21 Apr, 2020.)

“We hope that with the innovation we’ve seen in test development, we could see tests that you could buy at a drug store, swab your nose or collect saliva, run the test, and receive results within minutes at home, once these tests become available.” – Stephen Hahn

“The recommendations provided today are intended to help get tests to market that are simple enough to use at home, similar to a pregnancy test,” FDA commissioner Stephen Hahn said in a statement. “We hope that with the innovation we’ve seen in test development, we could see tests that you could buy at a drug store, swab your nose or collect saliva, run the test, and receive results within minutes at home, once these tests become available.”

The template makes several specific recommendations intended to reduce the risks associated with performing a test at home. For example, sponsors are directed to use either anterior nasal swabs, mid-turbinate swabs or saliva as the sample type, because collection of nasopharyngeal or oropharyngeal swabs requires training and can cause patient harm such as choking or nosebleeds if performed incorrectly.

The template also specifies that test kits should include two sets of instructions, one for self-testing and one for testing somebody else. The instructions should be written in Quick Reference Instruction (QRI) format and limited to one or two pages in length, the agency said.

The template also recommends that test results displayed to the user be simple: positive, negative or invalid. Users should be instructed to consult a physician if they still have concerns after getting a negative result, the FDA says.

This is the seventh EUA template the FDA has released in the fight against COVID-19. In addition to molecular diagnostic and serology templates for commercial and lab use, the agency has also created templates for antigen tests and home specimen collection. The templates are updated as additional information becomes available. (Also see "First US Home Collection COVID-19 Test Gets Green Light" - Medtech Insight, 21 Apr, 2020.)

おすすめのニュース&レポート

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。